171 related articles for article (PubMed ID: 16613007)
1. [An AT-II blocker in patients with type II diabetes and arterial hypertension].
Ametov AS; Demidova TIu; Kosykh SA
Klin Med (Mosk); 2006; 84(2):50-5. PubMed ID: 16613007
[TBL] [Abstract][Full Text] [Related]
2. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
de la Sierra A; Ram CV
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S1-3. PubMed ID: 18093407
[TBL] [Abstract][Full Text] [Related]
3. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin blockade with eprosartan: vascular and functional implications.
Ram CV
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
[TBL] [Abstract][Full Text] [Related]
5. Rationale, design and methods of the OSCAR study: observational study on cognitive function and systolic blood pressure reduction in hypertensive patients.
Pathak A; Hanon O; Negre-Pages L; Sevenier F;
Fundam Clin Pharmacol; 2007 Apr; 21(2):199-205. PubMed ID: 17391293
[TBL] [Abstract][Full Text] [Related]
6. Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
Shlyakhto E
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S13-8. PubMed ID: 18093409
[TBL] [Abstract][Full Text] [Related]
7. Effects of eprosartan on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction.
Voors AA; van de Wal RM; Hartog JW; Vijn RG; Hummel YM; Plokker TW; van Veldhuisen DJ; Jaarsma W
Cardiovasc Drugs Ther; 2010 Feb; 24(1):33-40. PubMed ID: 20229056
[TBL] [Abstract][Full Text] [Related]
8. The effect of treatment with eprosartan on pulse pressure: factors predicting response.
de la Sierra A; Muñoz A; Arcos E; López JS; Relats J;
Can J Cardiol; 2004 Oct; 20 Suppl C():17C-22C. PubMed ID: 16807619
[TBL] [Abstract][Full Text] [Related]
9. Effects of eprosartan on mitochondrial membrane potential and H2O2 levels in leucocytes in hypertension.
Labiós M; Martínez M; Gabriel F; Guiral V; Ruiz-Aja S; Beltrán B; Muñoz A
J Hum Hypertens; 2008 Jul; 22(7):493-500. PubMed ID: 18385744
[TBL] [Abstract][Full Text] [Related]
10. Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting.
Conter HS; McKay DW; Reiz RJ
Can J Cardiol; 2004 Oct; 20 Suppl C():6C-10C. PubMed ID: 16807617
[TBL] [Abstract][Full Text] [Related]
11. Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
Ram CV; Rudmann MA
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1003-11. PubMed ID: 18035916
[TBL] [Abstract][Full Text] [Related]
12. The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension.
Teitelbaum I; Chilvers M; Reiz RJ
Can J Cardiol; 2004 Oct; 20 Suppl C():11C-16C. PubMed ID: 16807618
[TBL] [Abstract][Full Text] [Related]
13. Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
Rupp H
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S25-9. PubMed ID: 18093411
[TBL] [Abstract][Full Text] [Related]
14. Eprosartan: a review of its use in the management of hypertension.
Robins GW; Scott LJ
Drugs; 2005; 65(16):2355-77. PubMed ID: 16266204
[TBL] [Abstract][Full Text] [Related]
15. Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction.
Hartog JW; van de Wal RM; Schalkwijk CG; Miyata T; Jaarsma W; Plokker HW; van Wijk LM; Smit AJ; van Veldhuisen DJ; Voors AA
Eur J Heart Fail; 2010 Apr; 12(4):397-403. PubMed ID: 20154337
[TBL] [Abstract][Full Text] [Related]
16. [Stress-associated hypertension in the work place: results of the STARLET project].
Lüders S; Hammersen F; Kulschewski A; Frerichs A; Frieg R; Hahnheiser D; Reich G; Schnieders M; Schrandt G; Schrader J
Dtsch Med Wochenschr; 2006 Nov; 131(46):2580-5. PubMed ID: 17096303
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients.
Robles NR; Martín-Agueda B; López-Muñoz F; Alamo C;
Int J Clin Pract; 2005 Apr; 59(4):478-84. PubMed ID: 15853868
[TBL] [Abstract][Full Text] [Related]
18. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure.
Neumann J; Ligtenberg G; Oey L; Koomans HA; Blankestijn PJ
J Am Soc Nephrol; 2004 Nov; 15(11):2902-7. PubMed ID: 15504943
[TBL] [Abstract][Full Text] [Related]
19. The clinical profile of the angiotensin II receptor blocker eprosartan.
Hedner T
J Hypertens Suppl; 2002 Jun; 20(5):S33-8. PubMed ID: 12184062
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study.
Garg JP; Ellis R; Elliott WJ; Hasabou N; Chua D; Chertow GM; Bakris GL
Am J Nephrol; 2005; 25(4):393-9. PubMed ID: 16088080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
